Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy

Head and Neck

Volumn 33, Issue 9, 2011, Pages 1366-1371

  Lee, Jang Jaer ^a,b   Cheng, Shih Jung ^a,b   Jeng, Jiiang Huei ^a,b   Chiang, Chun Pin ^a,b   Lau, Hon Ping ^a   Kok, Sang Heng ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

alendronate; jaws; osteoporosis; parathyroid hormone; tooth extraction

Indexed keywords

ALENDRONIC ACID; AMOXICILLIN; CHLORHEXIDINE; PARATHYROID HORMONE[1-34];

ADJUVANT THERAPY; AGED; ARTICLE; BISPHOPHONATE RELATED OSTEONECROSIS OF THE JAW; BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW; BONE DENSITY; BONE DESTRUCTION; BONE REGENERATION; CASE REPORT; CONSERVATIVE TREATMENT; DEBRIDEMENT; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; JAW OSTEONECROSIS; MANDIBLE; MOUTH MUCOSA; OSTEOPOROSIS; PAIN; PANORAMIC RADIOGRAPHY; PATIENT REFERRAL; PRIORITY JOURNAL; SOFT TISSUE INFLAMMATION; TISSUE REGENERATION; TOOTH EXTRACTION; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BONE REGENERATION; DEBRIDEMENT; FEMALE; HUMANS; TERIPARATIDE;

EID: 80051758404     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21380     Document Type: Article

References (33)

1. Russell RGG, Watts NB, Ebetino FH, Rogers MJ,. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733-759.
2. Kimmel DB,. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2009; 86: 1022-1033.
3. Mundy GR,. Cytokines of bone. In:, Mundy GR, Martin TJ, editors. Physiology and pharmacology of bone. Berlin: Springer-Verlag; 1993. pp 185-214.
4. Allegra A, Oteri G, Nastro E, et al. Patients with bisphosphonate- associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 2007; 25: 164-169.
5. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62: 6538-6544. (Pubitemid 35364119)
6. Marx RE,. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117. (Pubitemid 37064711)
7. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P,. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29: 1548-1558. (Pubitemid 47500128)
8. Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008; 42: 841-847.
9. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mebrotra B,. American Association of Oral and Maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009; 67: 2-12.
10. Marx RE, Cillo JE, Ulloa JJ,. Oral bisphosphonates induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397-2410. (Pubitemid 350100982)
11. Migliorati CA, Schubert MM, Peterson DE, Senida LM,. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104: 83-93. (Pubitemid 40847755)
12. Shimura K, Shimazaki C, Taniguchi K, et al. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol 2006; 84: 343-345. (Pubitemid 46606576)
13. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 2007; 65: 1321-1327. (Pubitemid 46907400)
14. Nastro E, Musolino C, Allegra A, et al. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol 2007; 117: 181-187. (Pubitemid 46496803)
15. O'Ryan FS, Khoury S, Liao W, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg 2009; 67: 1363-1372.
16. Engroff SL, Kim DD,. Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction? J Oral Maxillofac Surg 2007; 65: 2374-2385. (Pubitemid 47588586)
17. Nocini PF, Saia G, Bettini G, et al. Vascularized fibula flap reconstruction of the mandible in bisphosphonate-related osteonecrosis. Eur J Surg Oncol 2009; 35: 373-379.
18. Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonate. Laryngoscope 2006; 116: 115-120. (Pubitemid 44383974)
19. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001; 16: 1846-1853. (Pubitemid 32911491)
20. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441. (Pubitemid 32402100)
21. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26: 688-703. (Pubitemid 41127277)
22. Andreassen TT, Ejersted C, Oxlund H,. Intermittent treatment of PTH improves callus formation and mechanical strength of healing rat fracture. J Bone Miner Res 1999; 14: 960-968. (Pubitemid 29262891)
23. Barnes GL, Kakar S, Vora S, Morgan EF, Gerstenfeld LC, Einhorn TA,. Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J Bone Joint Surg 2008; 90: 120-127. (Pubitemid 351329130)
24. Hunziker J, Wronski TJ, Miller SC,. Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. J Dent Res 2000; 79: 1431-1438. (Pubitemid 32489452)
25. Miller SC, Hunziker J, Mecham M, Wronski TJ,. Intermittent parathyroid hormone administration stimulates bone formation in the mandibles of aged ovariectomized rats. J Dent Res 1997; 76: 1471-1476. (Pubitemid 127732699)
26. Rao MV, Berk J, Almojaly SA, et al. Effects of platelet-derived growth factor, vitamin D and parathyroid hormone on osteoblasts derived from cancer patients on chronic bisphosphonate therapy. Int J Mol Med 2009; 23: 407-413.
27. Murray TM, Rao LG, Rizzoli RE,. Interactions of parathyroid hormone, parathyroid-related proteins and their fragments with conventional and non-conventional sites. In:, Bilezikian JP, Marcus R, Levine MA, editors. The parathyroids, New York: Raven; 1994. pp 185-212.
28. Ma YL, Bryant HU, Zeng Q, et al. New bone formation with teriparatide (human parathyroid hormone-(1-34)) is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 2008; 144: 2008-2015. (Pubitemid 36543341)
29. Komatsubara S, Mori S, Mashiba T, et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 2004; 19: 999-1005. (Pubitemid 41103457)
30. Dobnig H, Stepan JJ, Burr DB, et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res 2009; 24: 1998-2006.
31. Harper RP, Fung E,. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007; 65: 573-580. (Pubitemid 46343587)
32. Pleiner-Duxneuner J, Zwettler E, Paschalis E, Roschger P, Nell-Duxneuner V, Klaushofer K,. Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int 2009; 84: 159-170.
33. Girotra M, Rubin MR, Bilezikian JP,. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 2006; 7: 113-121. (Pubitemid 46049523)